TY - JOUR
T1 - In vitro degradation and erosion behavior of commercial PLGAs used for controlled drug delivery
AU - Walker, Jennifer
AU - Albert, Jason
AU - Liang, Desheng
AU - Sun, Jing
AU - Schutzman, Richard
AU - Kumar, Raj
AU - White, Cameron
AU - Beck-Broichsitter, Moritz
AU - Schwendeman, Steven P.
N1 - Publisher Copyright:
© 2022, Controlled Release Society.
PY - 2023/1
Y1 - 2023/1
N2 - Copolymers of lactic (or lactide) and glycolic (or glycolide) acids (PLGAs) are among the most commonly used materials in biomedical applications, such as parenteral controlled drug delivery, due to their biocompatibility, predictable degradation rate, and ease of processing. Besides manufacturing variables of drug delivery vehicles, changes in PLGA raw material properties can affect product behavior. Accordingly, an in-depth understanding of polymer-related “critical quality attributes” can improve selection and predictability of PLGA performance. Here, we selected 19 different PLGAs from five manufacturers to form drug-free films, submillimeter implants, and microspheres and evaluated differences in their water uptake, degradation, and erosion during in vitro incubation as a function of L/G ratio, polymerization method, molecular weight, end-capping, and geometry. Uncapped PLGA 50/50 films from different manufacturers with similar molecular weights and higher glycolic unit blockiness and/or block length values showed faster initial degradation rates. Geometrically, larger implants of 75/25, uncapped PLGA showed higher water uptake and faster degradation rates in the first week compared to microspheres of the same polymers, likely due to enhanced effects of acid-catalyzed degradation from PLGA acidic byproducts unable to escape as efficiently from larger geometries. Manufacturer differences such as increased residual monomer appeared to increase water uptake and degradation in uncapped 50/50 PLGA films and poly(lactide) implants. This dataset of different polymer manufacturers could be useful in selecting desired PLGAs for controlled release applications or comparing differences in behavior during product development, and these techniques to further compare differences in less reported properties such as sequence distribution may be useful for future analyses of PLGA performance in drug delivery. Graphical abstract: [Figure not available: see fulltext.]
AB - Copolymers of lactic (or lactide) and glycolic (or glycolide) acids (PLGAs) are among the most commonly used materials in biomedical applications, such as parenteral controlled drug delivery, due to their biocompatibility, predictable degradation rate, and ease of processing. Besides manufacturing variables of drug delivery vehicles, changes in PLGA raw material properties can affect product behavior. Accordingly, an in-depth understanding of polymer-related “critical quality attributes” can improve selection and predictability of PLGA performance. Here, we selected 19 different PLGAs from five manufacturers to form drug-free films, submillimeter implants, and microspheres and evaluated differences in their water uptake, degradation, and erosion during in vitro incubation as a function of L/G ratio, polymerization method, molecular weight, end-capping, and geometry. Uncapped PLGA 50/50 films from different manufacturers with similar molecular weights and higher glycolic unit blockiness and/or block length values showed faster initial degradation rates. Geometrically, larger implants of 75/25, uncapped PLGA showed higher water uptake and faster degradation rates in the first week compared to microspheres of the same polymers, likely due to enhanced effects of acid-catalyzed degradation from PLGA acidic byproducts unable to escape as efficiently from larger geometries. Manufacturer differences such as increased residual monomer appeared to increase water uptake and degradation in uncapped 50/50 PLGA films and poly(lactide) implants. This dataset of different polymer manufacturers could be useful in selecting desired PLGAs for controlled release applications or comparing differences in behavior during product development, and these techniques to further compare differences in less reported properties such as sequence distribution may be useful for future analyses of PLGA performance in drug delivery. Graphical abstract: [Figure not available: see fulltext.]
KW - Controlled drug release
KW - Long-term drug release
KW - PLGA
KW - Polymer in vitro behavior
UR - http://www.scopus.com/inward/record.url?scp=85131510947&partnerID=8YFLogxK
U2 - 10.1007/s13346-022-01177-8
DO - 10.1007/s13346-022-01177-8
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35672653
AN - SCOPUS:85131510947
SN - 2190-393X
VL - 13
SP - 237
EP - 251
JO - Drug Delivery and Translational Research
JF - Drug Delivery and Translational Research
IS - 1
ER -